| Control group | Group-1 | Group-2 | Group-3 | |
---|---|---|---|---|---|
WB (relative gray value) | Bax | 0.08 ± 0.02 | 0.18 ± 0.12** | 0.17 ± 0.17** | 0.17 ± 0.02** |
bcl-2 | 0.17 ± 0.02 | 0.07 ± 0.01** | 0.09 ± 0.01** | 0.09 ± 0.01** | |
CD31 | 0.75 ± 0.04 | 0.16 ± 0.02** | 0.16 ± 0.04** | 0.2 ± 0.01** | |
p-VEGFR-2 | 0.26 ± 0.02 | 0.16 ± 0.03** | 0.18 ± 0.01** | 0.19 ± 0.01** | |
MMP-2 | 0.71 ± 0.02 | 0.29 ± 0.03** | 0.3 ± 0.02** | 0.29 ± 0.01** | |
IF (positive rate%) | Bax | 3.37% ± 0.91 | 20.97 ± 2.09** | 19.13 ± 2.78** | 19.73 ± 1.52** |
bcl-2 | 17.17 ± 1.69 | 3.23 ± 1.35** | 2.43 ± 0.79** | 2.57 ± 0.5** | |
CD31 | 24.1 ± 1.15 | 6.73 ± 1.47** | 9.53 ± 1.6** | 9.7 ± 1.96** | |
p-VEGFR-2 | 16.77 ± 1.03 | 3.0 ± 0.29** | 3.83 ± 0.61** | 4.07 ± 1.04** | |
MMP-2 | 13.2 ± 1.53 | 2.77 ± 0.54** | 2.87 ± 0.49** | 2.93 ± 0.69** | |
IHC (positive rate%) | Bax | 13.2% ± 1.07 | 34.17 ± 1.11** | 32.83 ± 0.95** | 32.77 ± 1.16** |
bcl-2 | 31.73 ± 1.67 | 13.33 ± 1.59** | 14.63 ± 1.48** | 13.87 ± 1.89** | |
CD31 | 36.1 ± 1.69 | 11.63 ± 1.2** | 12.67 ± 1.52** | 12.33 ± 2.24** | |
p-VEGFR-2 | 35.47 ± 2.93 | 17.1 ± 1.31** | 17.53 ± 1.6**8 | 18.23 ± 1.25** | |
MMP-2 | 34.9 ± 2.38 | 14.53 ± 1.17** | 15.27 ± 0.74** | 15.57 ± 2.75** |